Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome

@inproceedings{Fan2016ComparisonOC,
  title={Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome},
  author={Zhenwei Fan and Xuan Wang and Chunshan Zhao and Wei Wang and Tingting Yu},
  year={2016}
}
Objective: To investigate the efficacy and safety of decitabine combined with half the amount of CAG and CAG regimen alone. Methods: Comparison the effectiveness, overall survival and incidence of adverse reactions of 42 cases of MDS used decitabine combined with half the amount of CAG regimen (decitabine 20mg/m, once a day, d1-3, Accra neomycin 7mg/m… CONTINUE READING